Molecular Express announces award of SBIR contract from the National Institutes of Health to develop Viratrodes as a Biosensor for the Improved Diagnosis of Cancer PDF Print E-mail
Written by Administrator   
Thursday, 16 February 2012 11:46

Molecular Express will develop a highly sensitive biosensor that can detect circulating tumor cells and cancer biomarkers.  The viratrode technology, licensed from  the University of California, Irvine and developed by  Professor Gregory Weiss and Chancellor’s Professor Reginald Penner, incorporates a bioaffinity layer consisting of a “kelp forest” of filamentous phage particles, with a sensitive electronic area detector capable of detecting low nM concentrations of biomarkers.  The viratrode for this contract will be adapted with phage particles displaying multiple ligands to a particular cancer biomarker.  This project will lay the groundwork for the development of a point-of-care device capable of recognizing, capturing and quantifying tumor cells and biomarkers for prostate cancer in the circulating peripheral blood (and potentially other biofluids) of a cancer patient.

Last Updated on Monday, 19 March 2012 16:09